BHCM
DNA icon

Brevan Howard Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Brevan Howard Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,401
Closed -$94.7K – 2227
2025
Q4 		$94.7K Buy
+11,401
New +$123K ﹤0.01% 1678
2025
Q2 		– Sell
-10,145
Closed -$57.8K – 1874
2025
Q1 		$57.8K Buy
+10,145
New +$103K ﹤0.01% 1085
2024
Q3 		– Sell
-13,814
Closed -$185K – 1206
2024
Q2 		$185K Buy
13,814
+5,418
+65% +$162K ﹤0.01% 906
2024
Q1 		$390K Buy
8,396
+206
+3% +$10.7K ﹤0.01% 549
2023
Q4 		$554K Buy
8,190
+5,317
+185% +$326K 0.01% 439
2023
Q3 		$208K Sell
2,873
-14,591
-84% -$1.17M ﹤0.01% 320
2023
Q2 		$1.3M Hold
17,464
– – 0.03% 77
2023
Q1 		$929K Buy
+17,464
New +$1.11M 0.02% 85

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's DNA Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 11,401 shares — an estimated $94.7K sold.

Brevan Howard Capital Management first reported a position in DNA in Q1 2023 and held it in 8 quarters. The position peaked at $1.3M in Q2 2023. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 11,401 Ginkgo Bioworks shares in Q1 2026, an estimated $94.7K.
  • Brevan Howard Capital Management first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 8 quarters.
  • Brevan Howard Capital Management's Ginkgo Bioworks position peaked at $1.3M in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.